News & Updates

First-line rucaparib boosts PFS in ovarian cancer regardless of HRD status
First-line rucaparib boosts PFS in ovarian cancer regardless of HRD status
15 Sep 2022 byRoshini Claire Anthony

First-line rucaparib maintenance therapy extends progression-free survival (PFS) in patients with ovarian, fallopian tube, or primary peritoneal cancer, according to results of the phase III ATHENA-MONO trial presented at the ESMO Gynaecological Cancers Conference 2022.

First-line rucaparib boosts PFS in ovarian cancer regardless of HRD status
15 Sep 2022
Older age, itch, pain predict depression in atopic dermatitis
Older age, itch, pain predict depression in atopic dermatitis
15 Sep 2022

Depressive symptoms are common among adults with atopic dermatitis (AD) severity and may fluctuate over time, reveals a study. Persistent depression is significantly associated with older age, male sex, severe itch, and skin pain, among others.

Older age, itch, pain predict depression in atopic dermatitis
15 Sep 2022